Ignite Creation Date:
2024-05-06 @ 8:19 AM
Last Modification Date:
2024-10-26 @ 11:58 AM
Study NCT ID:
NCT02713295
Status:
COMPLETED
Last Update Posted:
2020-04-15
First Post:
2016-03-15
Brief Title:
A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece
Sponsor:
AbbVie
Organization:
AbbVie
Study Overview
Official Title:
A Non-interventional Prospective Cohort Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece
Status:
COMPLETED
Status Verified Date:
2020-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CONCORDIA
Brief Summary:
This study estimates the treatment goal achievement rate depicts the implementation of the Progressive Psoriasis Initiative PPI recommendations regarding treatment modifications and transitioning and assesses patient adherence and persistence with adalimumab therapy in the routine clinical practice in Greece
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None